In the preceding three months, 7 analysts have released ratings for WAVE Life Sciences (NASDAQ:WVE), presenting a wide array of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 4 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 2 | 0 | 0 | 0 |
| 3M Ago | 0 | 2 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $19.14, along with a high estimate of $24.00 and a low estimate of $14.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 10.27%.
Decoding Analyst Ratings: A Detailed Look
A clear picture of WAVE Life Sciences's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Andrew S. Fein | HC Wainwright & Co. | Maintains | Buy | $22.00 | $22.00 |
| Whitney Ijem | Canaccord Genuity | Announces | Buy | $19.00 | - |
| Tiago Fauth | Wells Fargo | Lowers | Overweight | $21.00 | $24.00 |
| Cheng Li | Oppenheimer | Announces | Outperform | $24.00 | - |
| Samantha Semenkow | Citigroup | Announces | Buy | $16.00 | - |
| Yun Zhong | Wedbush | Maintains | Outperform | $18.00 | $18.00 |
| Michael Freeman | Raymond James | Announces | Outperform | $14.00 | - |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to WAVE Life Sciences. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of WAVE Life Sciences compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for WAVE Life Sciences's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
Capture valuable insights into WAVE Life Sciences's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on WAVE Life Sciences analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Delving into WAVE Life Sciences's Background
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Financial Insights: WAVE Life Sciences
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Challenges: WAVE Life Sciences's revenue growth over 3M faced difficulties. As of 30 June, 2025, the company experienced a decline of approximately -55.82%. This indicates a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: WAVE Life Sciences's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -580.17%, the company may face hurdles in effective cost management.
Return on Equity (ROE): WAVE Life Sciences's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -32.45%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): WAVE Life Sciences's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -18.67%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.16, WAVE Life Sciences adopts a prudent financial strategy, indicating a balanced approach to debt management.
How Are Analyst Ratings Determined?
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
